We unleash insight, innovation and agility to transform lives by advancing the products and business of cancer care.

LEARN MORE ABOUT CHURCHILL PHARMACEUTICALS

Improving oral oncolytics through SoluMatrix® Fine Particle Technology™

LEARN MORE ABOUTSOLUTMATRIX® TECHNOLOGY

Leveraging SoluMatrix® Fine Particle Technology™ to develop needed therapies for patients living with genitourinary cancer

LEARN MORE ABOUT OUR PIPELINE
Next
Prev
Arrow Down

Bringing value to cancer care

Churchill Pharmaceuticals brings true value to cancer care.

We provide quality, orally delivered oncology products with optimized clinical profiles including enhanced efficacy, safety and efficiency. Our commitment to responsibly deliver these advantages to the patients, payers, and healthcare communities we serve is at the core of our business.

LEARN MORE ABOUT CHURCHILL
value Care

About Us

The Churchill team pairs depth-of-experience with an agile, entrepreneurial approach to responsibly bring forward improved oral oncology products.

LEARN MORE ABOUT CHURCHILL

Pipeline

Leveraging SoluMatrix® Fine Particle Technology™ to develop needed therapies for patients living with genitourinary cancer.

view our PIPELINE

Technology

Improving oral oncolytics through SoluMatrix® Fine Particle Technology™

VIEW OUR TECHNOLOGY

Latest Media

Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study
November 22, 2017

The Effect of Food on the Absorption of Abiraterone Acetate from a Fine Particle Dosage Form: A Randomized Crossover Trial in Healthy Volunteers
November 16, 2017

Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA™ by the U.S. FDA

KING OF PRUSSIA, Pa., July 20, 2017 /PRNewswire/ -- Churchill Pharmaceuticals, LLC (Churchill), a privately held company devoted to expanding treatment options...
July 20, 2017